摘要
目的：研究肝细胞癌p16蛋白及EGFR的表达及其临床病理学的意义。方法：应用p16蛋白及EGFR抗体，用S－P免疫组织化学技术进行观察。结果：50例肝细胞癌中32例（64％）p16蛋白阳性，36例（72％）EGFR阳性。P16蛋白阳性率在高分化型（包括梁状型及假腺管型）为88％（22／25），而低分化型（包括实团型与纤维硬化型）为40％（10／25），两者有明显的统计学差异（P＜0．01）。高分化型EGFR阳性率为52％（13／25），而低分化型为92％（23／25），两者也有明显差异（P＜0．01）。结论：P16及EGFR表达与肝细胞癌组织学分型及分级有关。
Objective:To study expressions of p16 protein and EGFR and their clinicopathalogical significances in hepatocellular carcinoma. Methods: Using S-P immunohistochemical technique with p16 protein and EGFR antibodies, 50 cases with the tumor were investigated. Results:32 cases (64%) were posititve for p16 protein and 36 cases (72% ) for EGFR in 50 cases with hepatocellular carcinoma.The rate of p16 in well differentiated type (including the trabecular and the pseudo-glandular) was 88% (22/25), and the poorly differentiated one (including the compact and the scirrhous) 40% (10/25), with statisticlly significant difference between them (P<0.01).The rate of EGFR in the well-differentiated was 52% (13/25) and the poorly differentiated 92% (23/25), also with statistically significant difference (P<0.01) Conclusions:The expressions of p16 and ECFR may be related to histological typing and grading of the tumor.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1999年第1期37-38,85,共3页
Chinese Journal of Cancer
关键词
肝肿瘤
P16基因
MTS1
EGFR
Hepatocellular carcinoma
p16 protein
EGFR
Immunochistochemistry
